Ritedose Meets Workforce Demand with RISE Program Partnership with InSpring and Benedict College
COLUMBIA, SC – October. 8, 2024 – To meet a need for demanding company roles, The Ritedose Corporation (Ritedose) partnered with inSpring and Benedict College to develop RISE, a workforce initiative for international STEM students at the Historically Black College and University (HBCU).
Ritedose is Proud to Partner with Verona Pharma to Deliver First-In-Class COPD Drug, Ohtuvayre (ensifentrine)*
September 17, 2024 -- The Ritedose Corporation, Inc. (Ritedose), the largest CDMO in the United States specializing in sterile Blow Fill Seal (BFS) production of unit dose solutions for the ophthalmic and respiratory markets, is proud to partner with Verona Pharma plc (Nasdaq: VRNA) as the development and manufacturing partner
Ritedose Pharmaceuticals Continues Tradition of Giving Back – Increases its Annual Donation to Unprecedented Amount of 1 Million Doses of Respiratory Medications to Dispensary of Hope for Low-income and Chronically lll Patients
COLUMBIA, S.C., August 12, 2024 – Ritedose Pharmaceuticals, a division of The Ritedose Corporation (Ritedose), the leading contract development and manufacturing organization (CDMO) specializing in sterile Blow Fill Seal (BFS) production, announces today that it will donate 1 Million (1M) doses to the national charitable medication distributor, Dispensary of Hope,
Ritedose Named Top 2023 Fundraiser by the American Heart Association
COLUMBIA, S.C. July 29, 2024 – Working together, The Ritedose Corporation (Ritedose) employees raised more than $77,000 during the company’s annual Field Day event this spring in support of the American Heart Association. Additionally, the Association recognized Ritedose as the #1 Field Day company in the nation for 2023.
Ritedose Interns Volunteer for Food Distribution at State’s Largest Food Bank, Harvest Hope
COLUMBIA, S.C., July 12, 2024 – Eight interns from The Ritedose Corporation (Ritedose) volunteered at the Harvest Hope, South Carolina’s largest food distribution charity this month—packaging boxes of food for needy families on July 10. The humanitarian work was part of the Ritedose summer internship program, where student-employees volunteer for
Ritedose, the Leading Pharmaceutical Manufacturer (CDMO) Specializing in Sterile Blow-Fill-Seal, Expands its BFS Capacity to Meet the Growing Demand for Ophthalmic and Respiratory Medications
COLUMBIA, S.C. June 20, 2024 – The Ritedose Corporation (Ritedose), the leading contract development and manufacturing organization (CDMO) specializing in sterile Blow Fill Seal (BFS) production, announces a significant expansion of its production capabilities to meet the demand for ophthalmic and respiratory medications.
Ritedose, South Carolina’s Leading Pharmaceutical Manufacturer, Buys 105 Acres of Land for Major Expansion.<br><em>50-percent growth in pharmaceutical manufacturing and sales spurs expansion, job creation</em>
Columbia, S.C. (February 22, 2024) — The Ritedose Corporation (Ritedose) today announced a major expansion of its rapidly-growing pharmaceutical company with the recent purchase of 105 acres from the Midlands Technical College Enterprise Campus in Richland Northeast.
Ritedose Pharmaceuticals Launches <em>Cromolyn Sodium Inhalation Solution, USP (20 mg/2 ml)</em>
COLUMBIA, S.C. (August 24, 2023) – Ritedose, a pharmaceutical manufacturer located in South Carolina, launched a new sterile unit dose generic product, Cromolyn Sodium Inhalation Solution, USP (20 mg/2 ml). The single-dose vial product joins a range of other inhalation solutions produced by Ritedose Pharmaceuticals and is available in cartons
Ritedose Launches <em>Albuterol Sulfate Inhalation Solution 0.5% (5 mg/mL)</em> to Meet National Drug Shortage
COLUMBIA, S.C. (May 9, 2023) – Ritedose, a 503B outsourcing facility located in South Carolina, just launched a new unit dose vial product, Albuterol Sulfate Inhalation Solution 0.5% (5 mg/mL). It is a ready-to-use drug shortage solution for hospital pharmacies across the country. Ritedose is a division of The Ritedose
Ritedose Reaches Milestone with Asset Purchase <br><em>Becomes largest generic drug maker of its kind</em>
COLUMBIA, S.C.—The Ritedose Corporation, LLC now offers the most complete nebulized inhalation drug portfolio in the industry with the purchase of the Arformoterol Tartrate asset from PAI Pharma of Greenville, S.C.
- 1
- 2
Recent Comments